Clinical Trial

Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a 12-month, single center, three-arm parallel design, double-blind, randomized clinical trial, to compare the effects of supplemental dietary fiber and metformin (MET) alone and in combination over 12 months on glucose metabolism (insulin resistance \[IR\]), inflammation and BMI in adolescents with obesity and IR, and to assess the relationship between therapeutic intervention(s) and changes in gut microbiome composition and function. Since MET and FIBER have been shown to reduce weight and increase insulin sensitivity through distinct but overlapping mechanisms of action, our central hypothesis is that the combination of FIBER + MET will have a synergistic effect and be more effective than FIBER or MET alone in improving metabolic function (IR) and reducing BMI and inflammation in adolescents with obesity, IR and family history (FM) of T2DM. .
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-10-01; most recent amendment 2025-11-14.
Status change: Not Yet Recruiting → Recruiting 2022-01-06
Trial Details
NCT Number NCT04578652
Lead Sponsor University of Alberta
Conditions Obesity, Childhood, Insulin Resistance
Enrollment 90 participants
Start Date 2021-10-22
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-11-17